DNA tests help assess metastasis risk of melanoma

03/25/2014 | Dermatology Times online

A gene expression profiling test can be used to evaluate the risk that primary cutaneous melanomas will metastasize after a negative sentinel lymph node biopsy. Researchers analyzed data involving 217 patients. "This gives clinicians a better way of identifying high-risk patients," said dermatologist Pedram Gerami.

View Full Article in:

Dermatology Times online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA